mProX™ Human CDK2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryBased on this stable cell line, we also provide cell-based in vitro assays to evaluate the effects of your compounds or antibodies.
Product Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Melissa
Verified Customer
Sharon
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 CDK2 is a target in breast cancers including IBC.
13 breast cancer cell lines, including IBC cells (SUM149 and KPL4), were subjected to an eastern blot, which revealed that the cyclin E/CDK2 pathway was activated, especially in TNBC lines.
Ref: Alexander, Angela, et al. "Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer." Oncotarget 8.9 (2017): 14897.
Pubmed: 28107181
DOI: 10.18632/oncotarget.14689
Research Highlights
Prior CDK2 inhibitors had off-target side effects and were nonspecific. A potential treatment option for CDK2-dependent malignancies is the creation of novel CDK2 inhibitors.
Tadesse, Solomon, et al. "Targeting CDK2 in cancer: challenges and opportunities for therapy." Drug discovery today 25.2 (2020): 406-413.
Pubmed:
31839441
DOI:
10.1016/j.drudis.2019.12.001
Although active CDK2 targets cyclin E for destruction, high levels of cyclin E often indicate inactive CDK2. Nevertheless, large levels of cyclin E are sometimes thought to be a sign of increased CDK2 activity.
Sakurikar, Nandini, and Alan Eastman. "Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1." Cell Cycle 15.9 (2016): 1184-1188.
Pubmed:
26986210
DOI:
10.1080/15384101.2016.1160983
